BVI, the fastest growing diversified company in ophthalmology, today announced the European launch of CryoTreq – the world’s first single-use, handheld cryo-surgery device for ophthalmology.
The product was developed in partnership with Prof. Stanislao Rizzo*, a retinal surgeon and Professor at University of Florence. This stand-alone device for cryo-surgery, functions without external connections to equipment, gas tanks or power and does not require any service or maintenance.
During the last few years, CryoTreq has been developed to modernize a well-proven method for treating sight-threatening retinal tears and detachments. “Within a minute of opening the sterile blister I am ready to treat retinal tears or detachment, whether I’m in my office or in the operating room. It’s never been this easy to perform a cryo procedure”, said Prof. Stanislao Rizzo from Italy.
CryoTreq enables a minimally invasive ab externo approach to treat retinal tears and detachments, providing an alternative to laser photocoagulation – especially for lesions located towards the anterior of the eye. It requires minimal time for preparation, is easy and intuitive to use, with a hand-controlled single button activation.
Like existing cryo equipment CryoTreq’s probe reaches temperatures as low as -88⁰C and the tip reaches cryogenic temperatures within 4 to 6 seconds after activation.
The launch will complement BVI’s existing posterior ophthalmic surgery portfolio, which includes high-quality and innovative single-use instruments, tamponades, dyes, enriched sterile saline solution and surgical equipment. “CryoTreq will be a game changer.
The ease of use and efficiency will make cryo-surgery accessible to more surgeons and their patients. We believe surgeons will, over time, replace use of many laser-based procedures with CryoTreq as well”, according to Shervin Korangy, BVI President and CEO.